Magnesium Lithospermate B 是从Salviae miltiorrhizae中提取的咖啡酸四聚体的衍生物。Magnesium Lithospermate B 被广泛用于心血管疾病的研究，并且可以防止葡萄糖引起的细胞内氧化损伤。Magnesium Lithospermate B 还能够抑制神经炎症并减轻神经变性。
| 生物活性 | Magnesium Lithospermate B, a derivative of caffeic acid tetramer, and is extracted fromSalviae miltiorrhizae. Magnesium Lithospermate B is widely used for the research of cardiovascular diseases, and it can protect against glucose-induced intracellular oxidative damage. Magnesium Lithospermate B also suppresses neuroinflammation and attenuates neurodegeneration[1][2][3]. |
体外研究
(In Vitro) | Magnesium Lithospermate B (20-60 μg/ml; 24 h) decreases LDH activity in the cultured supernatant, increases SOD activity in cardiomyocytes, reduces intracellular ROS and MDA levels, and significantly suppresses cardiomyocytes apoptosis[2].
Magnesium Lithospermate B (1-100 μg/ml) enhances proliferation of neural stem cells (NSCs) in a dose-dependent manner[3].
Magnesium Lithospermate B (10 μg/ml) promotes the differentiation in vitro of NSCs towards neurons[3].
|
体内研究
(In Vivo) | Magnesium Lithospermate B (2-8 mg/kg; p.o. once daily for 16 d) reduces the renal damage of oxidative stress through reduction of reactive oxygen species in old rats[1].
Magnesium Lithospermate B (0.5 μg/g; s.c. for 6 weeks) promotes the neurogenesis and improves the memory in PD models[3].
| Animal Model: | Young (5-month-old) and old (20-month-old) specific-pathogen-free male Sprague-Dawley rats[1] | | Dosage: | 2, 8 mg/kg | | Administration: | P.o. once daily for 16 days | | Result: | Reduced the protein expression of major subunits of nicotinamide adenine dinucleotide phosphate oxidase (Nox4 and p22phox), phospho-p38, nuclear factor-kappa B p65, cyclooxygenase-2, and inducible nitric oxide synthase.
Showed lower levels of senescence-related proteins such as p16, ADP-ribosylation factor 6, p53, and p21. |
|
| 分子量 | |
| 性状 | |
| Formula | |
| CAS 号 | |
| 中文名称 | |
| 结构分类 | - Phenylpropanoids
- Simple Phenylpropanols
|
| 来源 | - Plants
- Compositae
- Hemistepta lyrata
|
| 运输条件 | Room temperature in continental US; may vary elsewhere. |
| 储存方式 | | Powder | -20°C | 3 years | | 4°C | 2 years | | In solvent | -80°C | 6 months | | -20°C | 1 month |
|
| 溶解性数据 | In Vitro: DMSO : 100 mg/mL(134.97 mM;Need ultrasonic) 配制储备液 | 1 mM | 1.3497 mL | 6.7485 mL | 13.4971 mL | | 5 mM | 0.2699 mL | 1.3497 mL | 2.6994 mL | | 10 mM | 0.1350 mL | 0.6749 mL | 1.3497 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80℃, 6 months; -20℃, 1 month。-80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液，再依次添加助溶剂： ——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂： 10% DMSO 40%PEG300 5%Tween-80 45% saline Solubility: ≥ 2.5 mg/mL (3.37 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (3.37 mM，饱和度未知) 的澄清溶液。 以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。 2. 请依序添加每种溶剂： 10% DMSO 90% (20%SBE-β-CDin saline) Solubility: ≥ 2.5 mg/mL (3.37 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (3.37 mM，饱和度未知) 的澄清溶液。 以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。 *以上所有助溶剂都可在本网站选购。
|
